Company Overview of Ampersand Capital Partners
Ampersand Capital Partners is a private equity firm specializing in growth equity, expansion, recapitalizations, management buyouts, emerging growth, and corporate divestitures. It invests in lower middle market companies. The firm typically invests in healthcare and industrial sector. Within industrial sector, it focuses on product and process design software, instrumentation for the chemical processing, and environmental industries. Within healthcare sector, the firm focuses on laboratory services, diagnostic testing, regulatory testing, manufacturing support; laboratory products, scientific products, diagnostic products, specialty distribution; contract manufacturing, medical Devices and ...
55 William Street
Wellesley, MA 02481
Founded in 1988
Key Executives for Ampersand Capital Partners
Founder and Managing Partner
Partner, Chief Operating Officer, and Chief Compliance Officer
Managing Partner and Managing General Partner
Compensation as of Fiscal Year 2016.
Ampersand Capital Partners Key Developments
Ampersand Capital Partners Appoints Frank Witney as an Operating Partner
Sep 22 16
Ampersand Capital Partners has named Frank Witney, Ph.D, as an operating partner. Dr. Witney is working with Ampersand's investment team to identify and evaluate new investment opportunities as well as assist in the existing portfolio.He has a long and distinguished career in the laboratory products segment of the healthcare industry. Most recently, he served as president and CEO of publicly traded Affymetrix.
Avista Pharma and ATS Labs Seeks Acquisitions
Jul 6 15
Ampersand Capital Partners said it has appointed Patrick D. Walsh as Chief Executive Officer of Avista Pharma Solutions and ATS Labs, Inc. He will focus on expanding the service offerings of the combined business and evaluating additional acquisition opportunities.
Ampersand Capital Partners Announces Executive Appointments
Jun 29 15
Ampersand Capital Partners announced that it has appointed Patrick D. Walsh as Chief Executive Officer of Avista Pharma Solutions and Accuratus Labs. In conjunction with Mr. Walsh's appointment, Eric Hess has been named President and Chief Business Officer of the Accuratus Labs business unit.
Mr. Walsh has over 30 years of experience building high-achieving, contract development and manufacturing organizations serving the pharmaceutical industry. He will focus on expanding the service offerings of the combined business and evaluating additional acquisition opportunities. Mr. Walsh has led several high growth organizations over the course of his career including as CEO of AAI Pharma Services, CEO of Kadmus Pharmaceuticals, and president and COO of Gensia Sicor. In addition to his executive experience, Mr. Walsh has served on the boards of directors of various companies in the pharmaceutical, biotechnology, and contract service and manufacturing industries.
Similar Private Companies By Industry
Recent Private Companies Transactions